MELD score and antibiotics use are predictors of length of stay in patients hospitalized with hepatic encephalopathy

BMC Gastroenterol. 2014 Oct 17:14:185. doi: 10.1186/1471-230X-14-185.

Abstract

Background: Hepatic encephalopathy (HE) represents a significant burden to the healthcare system. The aim of this study was to determine factors influencing the hospital length of stay among patients hospitalized with HE.

Methods: A data warehouse query was performed to identify 316 patients with a first hospitalization during which HE occurred, between April 2010 and February 2012. Baseline and hospitalization characteristics were collected with IRB approval. A negative binomial multivariable model was used to control for potential confounders on the length of hospitalization.

Results: Median age was 59 years, and 60.4% of admitted patients were male. The median MELD score was 22 (IQR: 17-28). Median length of stay was 8 days (IQR: 3.25-14.25). After controlling for MELD score, female gender (2.2 days; p = 0.04), being initially admitted for a reason other than HE (liver-related: 7.6 days; p < 0.01 and non liver-related 10.7 days; p < 0.01) and receiving antibiotics other than rifaximin (10.5 days; p < 0.01) were associated with longer length of stay whereas hepatitis C (-3.1 days; p < 0.01) was associated with a shorter length of stay.

Conclusions: MELD score, gender, use of antibiotics other than rifaximin, reason for admission and hepatitis C are predictors readily available in clinic that can help identify patients at risk for longer length of stay.

MeSH terms

  • Aged
  • Anti-Bacterial Agents / therapeutic use*
  • Female
  • Hepatic Encephalopathy / complications*
  • Hepatic Encephalopathy / mortality
  • Hepatic Encephalopathy / therapy
  • Hepatitis C / complications
  • Hepatitis C / drug therapy
  • Hospital Mortality
  • Humans
  • Kidney Failure, Chronic / complications*
  • Length of Stay*
  • Male
  • Middle Aged
  • Patient Readmission
  • Retrospective Studies
  • Rifamycins / therapeutic use
  • Rifaximin
  • Sex Factors

Substances

  • Anti-Bacterial Agents
  • Rifamycins
  • Rifaximin